Sublocade

 

Sublocade is an extended-release, once-monthly subcutaneous injection formulation of buprenorphine used to treat moderate to severe opioid use disorder (OUD). Its clinical and pharmacological effects are derived directly from the active ingredient, buprenorphine. [1] (https://pmc.ncbi.nlm.nih.gov/articles/PMC7442141/), [2] (https://pdf.hres.ca/dpd_pm/00048406.PDF), [3] (https://m.youtube.com/shorts/Tau96pD8m48)


Core Pharmacological Mechanisms


• Partial Mu-Opioid Receptor Agonist: Buprenorphine binds to mu-opioid receptors in the brain but exhibits lower intrinsic activity (partial activation) compared to full agonists like heroin, methadone, or oxycodone. This provides enough receptor stimulation to suppress withdrawal symptoms and cravings without producing intense euphoria. [1] (https://go.drugbank.com/drugs/DB00921), [2] (https://www.medicalnewstoday.com/articles/drugs-sublocade-how-it-works), [3] (https://www.youtube.com/shorts/kdhmEsAW_z4)

• High Receptor Affinity: Buprenorphine possesses a very high binding affinity for the mu-opioid receptor—significantly tighter than morphine, fentanyl, or oxycodone. Because it binds so strongly and dissociates slowly, it physically blocks full agonist opioids from binding to the receptor, blunting or neutralizing their euphoric and rewarding effects. [1] (https://pmc.ncbi.nlm.nih.gov/articles/PMC7442141/), [2] (https://www.medicalnewstoday.com/articles/drugs-sublocade-how-it-works)

• Ceiling Effect: Because it is a partial agonist, the physiological and subjective effects of buprenorphine (such as respiratory depression, euphoria, and sedation) plateau at higher doses. This ceiling effect significantly lowers the risk of fatal overdose compared to full opioid agonists. [1] (https://www.nami.org/treatments-and-approaches/mental-health-medications/types-of-medication/buprenorphine-sublocade/), [2] (https://www.youtube.com/watch?v=9MWmWmCJNo0&t=36), [3] (https://go.drugbank.com/drugs/DB00921)

• Kappa-Opioid Receptor Antagonist: Buprenorphine also acts as an antagonist at kappa-opioid receptors, which may contribute to reductions in stress response, anxiety-like states, and hyperalgesia (increased sensitivity to pain). [1] (https://www.medicalnewstoday.com/articles/drugs-sublocade-how-it-works), [2] (https://www.youtube.com/watch?v=9MWmWmCJNo0&t=36)


Extended-Release Delivery and Pharmacokinetics


• Atrigel Delivery System: Sublocade uses a liquid polymer delivery system. When injected subcutaneously (under the skin) into the abdominal region by a healthcare provider, the fluid solidifies into a biodegradable depot upon contact with bodily fluids. [1] (https://www.sublocadehcp.com/pharmacology/buprenorphine-delivery), [2] (https://www.youtube.com/shorts/7xdy-S4Qs3U), [3] (https://pdf.hres.ca/dpd_pm/00048406.PDF)

• Controlled Slow Release: The depot slowly and continuously diffuses buprenorphine over a 28-day (monthly) period. [1] (https://www.sublocade.com/), [2] (https://www.youtube.com/shorts/7xdy-S4Qs3U)

• Stable Plasma Concentrations: Unlike daily sublingual or oral buprenorphine/Suboxone—which causes daily peaks and troughs in blood plasma levels—Sublocade maintains relatively steady therapeutic plasma concentrations of buprenorphine throughout the entire month. [1] (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209819s028lbl.pdf), [2] (https://www.sublocade.com/)

• Prolonged Clearance: Because buprenorphine is gradually released from the subcutaneous depot and has a long elimination half-life, detectable levels of buprenorphine can persist in the body for many months after a patient discontinues treatment. [1] (https://www.sublocadehcp.com/pharmacology/buprenorphine-delivery), [2] (https://www.youtube.com/watch?v=9MWmWmCJNo0&t=36)

A comprehensive review of receptor dynamics and delivery profiles can be found in the Buprenorphine Pharmacology Review on PubMed Central. [1] (https://pmc.ncbi.nlm.nih.gov/articles/PMC7442141/)

If you'd like to explore this further, let me know:

• Are you looking for information on how to transition from oral buprenorphine to Sublocade?

• Are you interested in side effects or drug interactions?

******

Buprenorphine SMILES String

Oc7ccc5c1c7O[C@H]3[C@]6(OC)[C@H](C[C@@]2([C@H](N(CC[C@@]123)CC4CC4)C5)CC6)[C@@](O)(C)C(C)(C)C

The SMILES (Simplified Molecular Input Line Entry System) string is a text-based representation of a molecular graph rather than a visual picture. For Sublocade's active ingredient, buprenorphine (molecular formula C29H41NO4), the SMILES notation represents its complex multi-ring morphinan structure. [1] (https://pubchem.ncbi.nlm.nih.gov/compound/Buprenorphine), [2] (https://en.wikipedia.org/wiki/Buprenorphine)


Buprenorphine SMILES String


text

Oc7ccc5c1c7O[C@H]3[C@]6(OC)[C@H](C[C@@]2([C@H](N(CC[C@@]123)CC4CC4)C5)CC6)[C@@](O)(C)C(C)(C)C

Use code with caution.

 [1] (https://en.wikipedia.org/wiki/Buprenorphine)


Key Structural Features Represented


• Morphinan Core. The nested ring numbers (1 through 7) map out the rigid pentacyclic morphinan skeleton derived from thebaine. [1] (https://www.ncbi.nlm.nih.gov/books/NBK459126/), [2] (https://pubchem.ncbi.nlm.nih.gov/compound/Buprenorphine), [3] (https://en.wikipedia.org/wiki/Buprenorphine)

• Stereochemistry. The @ and @@ symbols define the specific 3D spatial orientation at the chiral centers ([C@H], [C@@]), which is critical for its high binding affinity to the mu-opioid receptor. [1] (https://en.wikipedia.org/wiki/Buprenorphine)

• Cyclopropylmethyl Group. The CC4CC4 segment attached to the nitrogen (N) represents the cyclopropylmethyl substitution, which contributes to its partial agonist and kappa-antagonist profile. [1] (https://pubchem.ncbi.nlm.nih.gov/compound/Buprenorphine), [2] (https://en.wikipedia.org/wiki/Buprenorphine)

• Tert-Butyl Side Chain. The [C@@](O)(C)C(C)(C)C group at the end represents the bulky 2-hydroxy-3,3-dimethylbutan-2-yl side chain that increases lipophilicity and slows receptor dissociation. [1] (https://pubchem.ncbi.nlm.nih.gov/compound/Buprenorphine), [2] (https://en.wikipedia.org/wiki/Buprenorphine)

Licensed by Google

You can interactively explore the 2D molecular graph, 3D conformer, and related chemical descriptors on the PubChem Buprenorphine Compound Summary. [1] (https://pubchem.ncbi.nlm.nih.gov/compound/644073), [2] (https://molviewer.bio/compound/buprenorphine)

Would you like to look at the SMILES string for its primary active metabolite (norbuprenorphine), or explore how its chemical structure affects receptor binding?

Sublocade maintains steady-state plasma concentrations above the 2 ng/mL therapeutic threshold throughout the entire 28-day dosing interval. Unlike daily sublingual or transmucosal buprenorphine—which experiences sharp daily peaks and deep troughs—Sublocade delivers a flat, sustained exposure profile. [1] (https://www.sublocadehcp.com/pharmacology/plasma-levels), [2] (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209819s028lbl.pdf), [3] (https://www.opiant.com/admin/resources/dam/id/652/SUBLOCADE-Fact-Sheet.pdf)


Steady-State Exposure Breakdown


Clinical pharmacokinetic trials show how Sublocade's monthly maintenance doses compare to daily transmucosal buprenorphine (Subutex/Suboxone) at steady state (achieved after 4 to 6 months): [1] (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209819Orig1s000ClinPharmR.pdf), [2] (https://www.sublocadehcp.com/pharmacology/plasma-levels), [3] (https://www.opiant.com/admin/resources/dam/id/652/SUBLOCADE-Fact-Sheet.pdf)


Formulation & Dose Minimum Trough (\(C_{\text{min,ss}}\)) Average Exposure (\(C_{\text{avg,ss}}\)) Maximum Peak (\(C_{\text{max,ss}}\))

Sublocade 100 mg (Monthly) 2.48 ng/mL 3.21 ng/mL 4.88 ng/mL

Sublocade 300 mg (Monthly) 5.01 ng/mL 6.54 ng/mL 10.12 ng/mL

Transmucosal 8 mg (Daily) 0.81 ng/mL 1.71 ng/mL 5.35 ng/mL

Transmucosal 12 mg (Daily) 1.25 ng/mL 2.19 ng/mL 5.37 ng/mL

Transmucosal 24 mg (Daily) 1.54 ng/mL 2.91 ng/mL 8.27 ng/mL



Key Pharmacokinetic Takeaways


• Elimination of Daily Troughs: Even on a high daily dose of 24 mg transmucosal buprenorphine, plasma levels dip to a trough of 1.54 ng/mL before the next dose. Sublocade 100 mg keeps trough concentrations at 2.48 ng/mL, preventing end-of-dose withdrawal symptoms. [1] (https://www.opiant.com/admin/resources/dam/id/652/SUBLOCADE-Fact-Sheet.pdf)

• Opioid Blockade Threshold: Plasma concentrations of 2 to 3 ng/mL correspond to 70%–80% mu-opioid receptor occupancy, which is the threshold required to block the euphoric effects of exogenous opioids. Both the 100 mg and 300 mg maintenance regimens sustain levels above this threshold all month. [1] (https://pmc.ncbi.nlm.nih.gov/articles/PMC8016750/), [2] (https://www.sublocadehcp.com/pharmacology/plasma-levels)

• Initial Peak and Terminal Half-Life: Following each subcutaneous injection, plasma concentrations peak around 24 hours post-dose before settling into a slow decline. Because the polymer depot degrades gradually, Sublocade has an apparent terminal half-life of 43 to 60 days, meaning detectable plasma levels can persist for 12 months or longer after stopping treatment. [1] (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209819s000lbl.pdf), [2] (https://www.youtube.com/watch?v=nC2fj3USIL0&t=167), [3] (https://www.sublocadehcp.com/pharmacology/plasma-levels)

Detailed concentration-time curves and population pharmacokinetic models are available in the and the FDA Prescribing Information.

Would you like to see how mu-opioid receptor occupancy correlates with these plasma levels, or compare Sublocade's exposure profile to weekly/monthly Brixadi?

Sublocade maintains steady-state plasma concentrations above the 2 ng/mL therapeutic threshold throughout the entire 28-day dosing interval. Unlike daily sublingual or transmucosal buprenorphine—which experiences sharp daily peaks and deep troughs—Sublocade delivers a flat, sustained exposure profile. [1] (https://www.sublocadehcp.com/pharmacology/plasma-levels), [2] (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209819s028lbl.pdf), [3] (https://www.opiant.com/admin/resources/dam/id/652/SUBLOCADE-Fact-Sheet.pdf)

Steady-State Exposure Breakdown

Clinical pharmacokinetic trials show how Sublocade's monthly maintenance doses compare to daily transmucosal buprenorphine (Subutex/Suboxone) at steady state (achieved after 4 to 6 months): [1] (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209819Orig1s000ClinPharmR.pdf), [2] (https://www.sublocadehcp.com/pharmacology/plasma-levels), [3] (https://www.opiant.com/admin/resources/dam/id/652/SUBLOCADE-Fact-Sheet.pdf)

Formulation & Dose Minimum Trough (\(C_{\text{min,ss}}\)) Average Exposure (\(C_{\text{avg,ss}}\)) Maximum Peak (\(C_{\text{max,ss}}\))
Sublocade 100 mg (Monthly) 2.48 ng/mL 3.21 ng/mL 4.88 ng/mL
Sublocade 300 mg (Monthly) 5.01 ng/mL 6.54 ng/mL 10.12 ng/mL
Transmucosal 8 mg (Daily) 0.81 ng/mL 1.71 ng/mL 5.35 ng/mL
Transmucosal 12 mg (Daily) 1.25 ng/mL 2.19 ng/mL 5.37 ng/mL
Transmucosal 24 mg (Daily) 1.54 ng/mL 2.91 ng/mL 8.27 ng/mL


Key Pharmacokinetic Takeaways

• Elimination of Daily Troughs: Even on a high daily dose of 24 mg transmucosal buprenorphine, plasma levels dip to a trough of 1.54 ng/mL before the next dose. Sublocade 100 mg keeps trough concentrations at 2.48 ng/mL, preventing end-of-dose withdrawal symptoms. [1] (https://www.opiant.com/admin/resources/dam/id/652/SUBLOCADE-Fact-Sheet.pdf)
• Opioid Blockade Threshold: Plasma concentrations of 2 to 3 ng/mL correspond to 70%–80% mu-opioid receptor occupancy, which is the threshold required to block the euphoric effects of exogenous opioids. Both the 100 mg and 300 mg maintenance regimens sustain levels above this threshold all month. [1] (https://pmc.ncbi.nlm.nih.gov/articles/PMC8016750/), [2] (https://www.sublocadehcp.com/pharmacology/plasma-levels)
• Initial Peak and Terminal Half-Life: Following each subcutaneous injection, plasma concentrations peak around 24 hours post-dose before settling into a slow decline. Because the polymer depot degrades gradually, Sublocade has an apparent terminal half-life of 43 to 60 days, meaning detectable plasma levels can persist for 12 months or longer after stopping treatment. [1] (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209819s000lbl.pdf), [2] (https://www.youtube.com/watch?v=nC2fj3USIL0&t=167), [3] (https://www.sublocadehcp.com/pharmacology/plasma-levels)
Detailed concentration-time curves and population pharmacokinetic models are available in the and the FDA Prescribing Information.
Would you like to see how mu-opioid receptor occupancy correlates with these plasma levels, or compare Sublocade's exposure profile to weekly/monthly Brixadi?


No, Sublocade blood levels are not routinely measured for peaks and troughs in clinical practice. Unlike Coumadin (warfarin)—which has a narrow therapeutic window and requires regular blood tests (INR) to prevent dangerous bleeding or clotting—Sublocade is dosed based on clinical symptoms rather than blood concentrations. [1] (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209819s000lbl.pdf), [2] (https://emedicine.medscape.com/article/1641147-workup)


Why Routine Blood Monitoring Isn't Needed


• Wide Safety Margin. Buprenorphine is a partial mu-opioid agonist with a built-in ceiling effect for respiratory depression. Small fluctuations in blood levels do not carry the high toxicity risks seen with drugs like Coumadin or certain antibiotics.

• Predictable Depot Release. The subcutaneous polymer depot is specifically engineered to keep plasma levels consistently above the target threshold without requiring individualized dose titration based on lab draws. [1] (https://www.sublocadehcp.com/pharmacology/plasma-levels)

• Symptom-Driven Dosing. Clinicians adjust maintenance doses based on whether the patient reports cravings, withdrawal symptoms, or over-sedation—not a lab number. [1] (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209819s028lbl.pdf), [2] (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209819s000lbl.pdf)

• Slow Lab Turnaround. Quantitative serum buprenorphine tests require specialized liquid chromatography–tandem mass spectrometry (LC-MS/MS) at reference laboratories, taking several days to return results. This makes them impractical for immediate dosing decisions. [1] (https://ltd.aruplab.com/Tests/Pub/2012647), [2] (https://emedicine.medscape.com/article/1641147-workup)


What Labs Are Actually Monitored?


Instead of tracking drug peaks and troughs, providers monitor general health and treatment adherence through standard tests:

• Liver Function Tests (LFTs). Because buprenorphine is metabolized by the liver and Sublocade cannot be rapidly removed from the body once injected, providers check liver enzymes before starting treatment and periodically thereafter. [1] (https://www.sublocadehcp.com/pharmacology/plasma-levels), [2] (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209819s028lbl.pdf)

• Urine Drug Screens (UDS). Routine urine testing checks for the presence of buprenorphine and its metabolite to confirm medication metabolism, alongside screening for non-prescribed substances. Note that urine concentrations do not directly correlate with exact blood plasma levels. [1] (https://cdn.mdedge.com/files/s3fs-public/CP02109012.pdf), [2] (https://www.aafp.org/afp/2025/0400/buprenorphine-treatment-opioid-use-disorder), [3] (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209819s000lbl.pdf)


Rare Exceptions for Serum Testing


Quantitative blood testing exists, though it is rarely ordered outside of clinical research. A specialist might occasionally order a trough blood level right before the next scheduled injection if a patient is taking strong CYP3A4 enzyme inducers (which speed up buprenorphine breakdown) or experiencing unexplained withdrawal symptoms. [1] (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209819Orig1s000ClinPharmR.pdf), [2] (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209819s028lbl.pdf), [3] (https://www.sublocadehcp.com/pharmacology/plasma-levels), [4] (https://ltd.aruplab.com/Tests/Pub/2012647)

You can review standard monitoring protocols in the ARUP Laboratories Buprenorphine Serum Test Directory and the Sublocade FDA Prescribing Information.

Would you like to look at specific medications that interact with Sublocade (like CYP3A4 inhibitors or inducers), or explore how doctors manage sudden pain or surgery while a patient has an active depot?

For buprenorphine (the active small molecule in Sublocade), its chemical formula and primary metabolic reaction equations are summarized below.


Chemical Formula & Molecular Weight


• Molecular Formula: \(\text{C}_{29}\text{H}_{41}\text{NO}_4\)

• Molar Mass: \(467.64\text{ g/mol}\)


Primary Metabolic Equation (N-Dealkylation)


In the liver, buprenorphine is primarily metabolized by the CYP3A4 enzyme into its active metabolite, norbuprenorphine, by removing the cyclopropylmethyl group (\(\text{C}_4\text{H}_7\)):

\(\text{C}_{29}\text{H}_{41}\text{NO}_{4}\text{\ (Buprenorphine)}+\text{O}_{2}+\text{NADPH}+\text{H}^{+}\xrightarrow{\text{CYP3A4}}\text{C}_{25}\text{H}_{35}\text{NO}_{4}\text{\ (Norbuprenorphine)}+\text{C}_{4}\text{H}_{6}\text{O}+\text{NADP}^{+}+\text{H}_{2}\text{O}\)


Secondary Conjugation Equation (Glucuronidation)


Both buprenorphine and norbuprenorphine then undergo glucuronidation via UGT enzymes (such as UGT1A1 and UGT2B7) to become water-soluble for excretion:

\(\text{C}_{29}\text{H}_{41}\text{NO}_{4}+\text{UDP-glucuronic\ acid}\xrightarrow{\text{UGT}}\text{C}_{35}\text{H}_{49}\text{NO}_{10}\text{\ (Buprenorphine-3-glucuronide)}+\text{UDP}\)

You can view additional chemical identifiers, InChI keys, and reaction pathways on the PubChem Buprenorphine Compound Page and the DrugBank Buprenorphine Entry.

Were you looking for a different type of equation—such as a pharmacokinetic decay/elimination equation for the depot, or a receptor-binding affinity (\(K_{i}\)) equation?



Comments

Popular posts from this blog

Quality of Life

Ebola Vaccines

*65*